Get started with Myriad Oncology

Request more information from our team or explore ordering options and resources to bring Myriad Oncology testing into your practice.

Request information

Genetic testing from Myriad Oncology

Cancer treatment made clear

You are committed to identifying the best cancer treatments for your patients. Genetic testing can provide the answers you’re looking for to create personalized medical management plans for more effective patient care.

Genetic testing from Myriad Oncology

Cancer treatment made clear

You are committed to identifying the best cancer treatments for your patients. Genetic testing can provide the answers you’re looking for to create personalized medical management plans for more effective patient care.

Find treatment clarity in cancer complexity

Get the clarity you need to navigate each patient’s cancer diagnosis and treatment. Genetic testing helps you determine comprehensive cancer treatment options based on unique cancer features for each patient you treat – and increases their odds for a healthy future.

Myriad Oncology’s genetic tests offer:

  • Clinically actionable, comprehensive results
  • Fast, simple processes
  • Affordable access to testing

Explore Myriad Oncology’s genetic tests

Find the right test for each patient you treat.

BRACAnalysis CDx product signature

FDA-approved germline companion diagnostic test for patients with breast, ovarian, pancreatic and prostate cancer.

EndoPredict product signature

Genomic prognostic test for patients newly diagnosed with early-stage, estrogen-receptor-positive, HER2-negative breast cancer.

FOLR1/FRA product signature

IHC Test to identify patients with ovarian cancer who may qualify for treatment with mirvetuximab

MyChoice® CDx product signature

The most comprehensive FDA-approved tumor test that determines HRD status in women with ovarian cancer.

MyRisk™ product signature

Germline hereditary cancer test capable of identifying risk for 11 hereditary cancers.

Precise™ Tumor product signature

Discover and target important variants within tumors.

Prolaris® product signature

A genetic test for untreated men with prostate cancer that can determine how quickly the cancer is growing and cancer recurrence risk. 

Introducing Precise™ Oncology Solutions

Multiple genetic tests, one seamless experience.

Precise Oncology Solutions provides a streamlined testing experience that gives you the ability to receive comprehensive results from germline testing, tumor profiling and companion diagnostic options, including HRD† testing, with just one order.

Precise, MyChoice CDx, MyRisk, BRACAnalysis CDx test boxes
Precise Oncology Solutions

GERMLINE

[FDA-Approved]

BRACAnalysis CDx®

[Non-FDA-Approved]

MyRisk™

HRD STATUS

[FDA-Approved]

MyChoice®CDx

IHC STAINS

[FDA-Approved]

FOLR1/FRa

TUMOR PROFILING

[Non-FDA-Approved]

Precise™ Tumor

† For patients with ovarian cancer.

* Precise Tumor and MyRisk are not approved by the FDA. FOLR1/FRα is an FDA-approved assay performed according to the intended use.

PARPi can cut disease progression or death for gBRCA patients graphic
PARPi can cut disease progression or death for gBRCA patients graphic

Germline and tumor testing reveal the whole story

Tumor testing can identify changes in genes of cancer cells, but may present limitations including unknown variants, limited tumor tissue and missed large rearrangements. Germline testing evaluates for hereditary mutations and can inform targeted therapies and surgical decisions. Combine them both to uncover a patient’s full cancer story and create a powerful treatment plan.

A partner to you and your patients

Myriad has invested over 30 years in developing tests and solutions that help provide the best answers and care possible.

Our tests are: 

Accurate

Myriad offers industry-leading accuracy so you can feel confident in the results. From hereditary cancer to precision medicine, our tests are designed to give providers and patients the most accurate answers possible.

Myriad accuracy

Affordable

Myriad is committed to providing patients with access to accurate and affordable genetic results. Through excellent insurance coverage and financial assistance programs, providers and patients can feel confident knowing Myriad has options for each patient’s situation.

Affordable genetic testing results

Guide-line backed, actionable results

Myriad offers germline and tumor genomic tests designed to inform specific guideline-approved treatment options for each step in the patient’s journey, as well as available clinical trials.3,4 By delivering clear, actionable results in easy-to-understand reports, we empower you to build a personalized treatment plan, supporting patients with informed options at every step of their cancer journey.

Myriad actionable

Secure

Myriad believes that results and genetic information belong to the patient. We take multiple steps to ensure that the security and privacy of patient data is not compromised, and we believe that patients should be in control of their information.

Myriad ensures privacy and security

Myriad Oncology resources

0

Myriad Live

Come join in on open-door discussions about current topics in cancer genetics with Dr. Slavin, Myriad’s medical experts, and frequent external special guests. View the dates, times and topics below

0

Latest studies & publications

Stay current with clinical validation and utility publications and more.

0

Documents & forms

Find the Myriad documents and forms you need right here.

BRACAnalysisCDx Logo

Intended use – PMA intended use statement for BRACAnalysis CDx

BRACAnalysis CDx® is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein-coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.

Results of the test are used as an aid in identifying patients who are or may become eligible for treatment with the targeted therapies listed in Table 1 in accordance with the most recently approved therapeutic product labeling.

Table 1: companion diagnostic indications

Tumor type Biomarker Therapy
Breast cancer Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes
  • LYNPARZA® (olaparib)
  • TALZENNA® (talazoparib)
Ovarian cancer Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes
  • LYNPARZA® (olaparib)
  • ZEJULA® (niraparib)
Pancreatic cancer Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes
  • LYNPARZA® (olaparib)
Prostate cancer Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes
  • LYNPARZA® (olaparib)

This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, a single laboratory site located at 322 North 2200 West, Salt Lake City, Utah 84116.

LYNPARZA is a registered trademark of the AstraZeneca group of companies.